-
Mashup Score: 4IMWG Scientific and Working Committees - 11 month(s) ago
The International Myeloma Working Group has a scientific committee and a few working committees. Here are their members.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21International Myeloma Working Group (IMWG) Publications - 11 month(s) ago
The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
@paurotero @JKaufmanMD @szusmani @YiLinMDPhD @TomBmt133 @DrRakeshPopat @AjayNookaMD @H_Einsele @SurbhiSidanaMD @AjaiChari @End_myeloma @KweeYong2 @NoopurRajeMD @jmikhaelmd @chngwj @MyelomaOslo @JaimeLarraya @IMFmyeloma Here is a link to all prior IMWG guidelines and consensus statements. https://t.co/OsCjtEigdJ
-
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrqt4p #mmMRD #mmsm #ctsm @FDAOncology https://t.co/cABSxMTt0d
-
-
Mashup Score: 20International Myeloma Working Group (IMWG) Publications - 11 month(s) ago
The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
@paurotero @JKaufmanMD @szusmani @YiLinMDPhD @TomBmt133 @DrRakeshPopat @AjayNookaMD @H_Einsele @SurbhiSidanaMD @AjaiChari @End_myeloma @KweeYong2 @NoopurRajeMD @jmikhaelmd @chngwj @MyelomaOslo @JaimeLarraya @IMFmyeloma Here is a link to all prior IMWG guidelines and consensus statements. https://t.co/OsCjtEigdJ
-
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrqt4p #mmMRD #mmsm #ctsm @FDAOncology https://t.co/cABSxMTt0d
-
-
Mashup Score: 3Find a Support Group - 12 month(s) ago
We have facilitated a network of 150 myeloma-specific support groups that hold regular meetings in the U.S. So no matter where you are, we can help you find or create a multiple myeloma support group and connect with other survivors and caregivers.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
RT @IMFmyeloma: Don't Wait. Join a #Myeloma Support Group Now at https://t.co/5wvubguEaM https://t.co/9JRdpeY2yx
-
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrqt4p #mmMRD #mmsm #ctsm @FDAOncology https://t.co/cABSxMTt0d
-
-
Mashup Score: 20International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma - 12 month(s) ago
The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
I am thrilled to mentor @OkontaIngrid in the 2024 IMF Medical Student Scholars for Health Equity in Myeloma program! Excited to guide future leaders in addressing myeloma disparities. https://t.co/ifXXKkGtuU #IMFMedScholar #IMFMPOWER #HealthEquity #MyelomaResearch @jmikhaelmd
-
-
Mashup Score: 20International Myeloma Foundation Announces 2024 Medical Student Scholars for Health Equity in Myeloma - 12 month(s) ago
The International Myeloma Foundation (IMF) is proud to announce its selection of IMF Medical Student Scholars for Health Equity in Myeloma for 2024.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
I am thrilled to mentor @OkontaIngrid in the 2024 IMF Medical Student Scholars for Health Equity in Myeloma program! Excited to guide future leaders in addressing myeloma disparities. https://t.co/ifXXKkGtuU #IMFMedScholar #IMFMPOWER #HealthEquity #MyelomaResearch @jmikhaelmd
-
-
Mashup Score: 3The Mayo Clinic’s PragMMatic Study Is Now Accruing Newly Diagnosed Multiple Myeloma Patients - 12 month(s) ago
Mayo Clinic’s PragMMatic Study Accruing Newly Diagnosed Multiple Myeloma Patients A new clinical trial administered by the Mayo Clinic, the PragMMatic Study, is now accruing newly diagnosed multiple myeloma (NDMM) patients. Led by the IMF’s International Myeloma Working Group (IMWG) members Drs. S. Vincent Rajkumar and Shaji Kumar, the study is for the first time comparing the efficacy and side effect profiles of the three most common treatment regimens for NDMM patients. These regimens include the following:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
The Mayo Clinic’s PragMMatic Study Is Now Accruing Newly Diagnosed Multiple Myeloma Patients [Nov 27, 2023] @IMFmyeloma https://t.co/tZIrdUhn5U #mmsm @MayoMyeloma @MayoClinic @MayoClinicHS @VincentRK https://t.co/9lUEIRX2zC https://t.co/jkz9XFBQpM
-
IMWG Steering Committee and Scientific Committees. https://t.co/tQ6sxZ3COI